New pill takes on hard-to-treat lung cancer in major trial
NCT ID NCT07242274
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new targeted drug, JMKX001899, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 472 adults who have already tried at least one prior treatment will be randomly assigned to receive either the new drug or chemotherapy. The goal is to see if the new drug works better at slowing cancer growth and has fewer side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Beijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a pill plus immunotherapy and targeted radiation shrink lung tumors before surgery?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Cancer drug pralsetinib may change how the body processes other medications
- Blood test may let cancer patients take safe breaks from immunotherapy
- New pill takes on tough lung cancer mutation